Overcoming Anti-VEGF Resistance in Retinal Vascular Diseases

23 concepts19 papers1 proposal

Retinal vascular diseases, such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), have long relied on vascular endothelial growth factor (VEGF) inhibitors as the first-line standard of care. By neutralizing VEGF, these therapies successfully reduce fluid leakage and halt abnormal blood vessel growth. However, clinicians frequently encounter a frustrating therapeutic plateau: approximately 30% to 40% of DME patients and a substantial portion of nAMD patients fail to respond adequately, experiencing persistent subretinal fluid and recurrent leakage.

This phenomenon of anti-VEGF resistance presents a major clinical hurdle. When fluid accumulation becomes chronic, it causes irreversible damage to the retinal architecture, leading to subretinal fibrosis and permanent vision loss. To overcome this resistance, recent research has focused on uncovering the alternative molecular pathways driving non-response, developing multi-target therapeutics, and leveraging deep learning to predict patient outcomes before irreversible damage occurs.

The Molecular and Structural Drivers of Non-Response

To understand why single-target VEGF inhibition fails, we must look at the broader microenvironment of the diseased retina. In advanced or recalcitrant stages of vascular disease, leakage is rarely driven by a single growth factor. For instance, ignoring secondary pathways like Angiopoietin-2 (Ang-2) leaves underlying vascular destabilization unaddressed. As noted by Franziska Eckardt et al. in their 2025 study, targeting VEGF alone is often insufficient to stabilize the vascular bed in all patients. Similarly, Viktoria Deiters et al. observed that in chronic DME, persistent fluid despite long-term therapy indicates that VEGF ceases to be the sole driver of vascular permeability (Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema).

Beyond Ang-2, other molecular cascades contribute to this resistance. Alternative targets, such as the specific signatures of transfer RNA-derived small RNAs (tsRNAs) identified by Yingqian Peng et al. (Small RNA Sequencing Reveals Transfer RNA-derived Small RNA Expression Profiles in Retinal Neovascularization) and the Delta-like 4 pathway explored by Xianchun Yan et al. (Endothelial cells-targeted soluble human Delta-like 4 suppresses both physiological and pathological ocular angiogenesis), highlight a highly redundant angiogenic network that can bypass standard anti-VEGF blockades.

Furthermore, specific disease phenotypes introduce unique mechanical and structural challenges:

Overcoming Resistance via Multi-Targeting and Dose Escalation

To break through the therapeutic plateau, researchers have shifted toward two primary strategies: increasing the molecular dose or expanding the therapeutic target profile.

The first approach involves intensifying the anti-VEGF signal to overcome receptor saturation or high fluid turnover. Michael Hafner et al. utilized deep learning to demonstrate that escalating the dose of aflibercept from 2 mg to 8 mg significantly reduces persistent intraretinal fluid and pigment epithelial detachment in therapy-resistant nAMD patients, allowing for extended treatment intervals (Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration).

The second, more robust strategy relies on bispecific antibodies that simultaneously target multiple pathways. Faricimab, which inhibits both VEGF-A and Ang-2, has emerged as a powerful tool for recalcitrant cases. By dual-targeting, faricimab stabilizes the endothelial wall, tightens cell junctions, and reduces inflammation more effectively than pure anti-VEGF agents.

In a series of studies, Franziska Eckardt et al. showed that switching treatment-resistant nAMD patients to faricimab achieved significant anatomical improvements and extended the treatment interval by over 50% to 60%, drastically reducing patient burden (Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration; Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab). Similarly, Yingyi Lu et al. demonstrated the safety and efficacy of RC28-E, a novel bispecific antibody designed to prevent subretinal fibrosis and permanent tissue damage by moving beyond single growth factor targeting (Safety and Efficacy of Multiple Escalating Doses of RC28-E for Neovascular Age-Related Macular Degeneration: A Phase 1b Trial).

Standard Anti-VEGF Therapy:
[VEGF Signal] ───┤ [Anti-VEGF Agent] ───> Persistent Fluid / Destabilized Endothelium

Dual-Pathway Bispecific Therapy (e.g., Faricimab):
[VEGF Signal]  ───┤ ┌─────────────────┐
                    │ Bispecific Agent│ ───> Dry Macula / Stabilized Endothelium
[Ang-2 Signal] ───┤ └─────────────────┘

Predicting Non-Response with Deep Learning and Biomarkers

Because chronic fluid causes cumulative, irreversible damage, identifying non-responders early is critical. Researchers are leveraging machine learning and advanced optical coherence tomography (OCT) imaging to predict therapeutic outcomes before structural failure occurs.

Rather than looking at fluid volume alone, recent models focus on structural integrity and inflammatory markers. Fengjiao Li et al. identified that baseline counts of hyperreflective foci (HRF)—microscopic indicators of inflammation visible on OCT—independently predict visual recovery following anti-VEGF therapy in DME (Predictive value of hyperreflective foci for anti-VEGF therapeutic outcomes in different subtypes of diabetic macular edema: a retrospective analysis).

To scale these insights, Xian Song et al. developed a deep learning pipeline to automatically quantify the integrity of the outer retinal layers, specifically the ellipsoid zone and external limiting membrane. The authors proved that photoreceptor disruption is a far more potent predictor of persistent disease activity than fluid volume alone (Automatic quantification of retinal photoreceptor integrity to predict persistent disease activity in neovascular age-related macular degeneration using deep learning).

By combining these structural OCT features with systemic blood biomarkers, multimodal machine learning models can now forecast anatomical responses with high accuracy. Wenrui Lu et al. built a predictive model achieving an area under the curve (AUC) of 0.90, allowing clinicians to flag potential non-responders before initiating standard first-line injections (A machine learning model for predicting anatomical response to Anti-VEGF therapy in diabetic macular edema).

Similarly, in challenging conditions like chronic central serous chorioretinopathy, Tae Keun Yoo et al. developed DeepPDT-Net, a two-stage transfer learning framework that outperforms human specialists in predicting treatment success (DeepPDT-Net: predicting the outcome of photodynamic therapy for chronic central serous chorioretinopathy using two-stage multimodal transfer learning). These AI-driven tools shift the clinical paradigm from reactive drug-switching to proactive, personalized intervention.

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 19 papers
  2. Version 1 · 2026-10-04 · 18 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_anti_vegf_resistance_c6bc3384,
  title = {anti-VEGF resistance},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/anti-vegf-resistance/rdr_c6bc3384da84462ab68e1e0c25f1e92a},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}

This exact version (version 2, frozen text):

@misc{lacuna_anti_vegf_resistance_c6bc3384_v2,
  title = {anti-VEGF resistance},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/anti-vegf-resistance/rdr_c6bc3384da84462ab68e1e0c25f1e92a/v/2},
  note = {Version 2, frozen 2026-10-04. Accessed 2026-11-22},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake